⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BFRIW News
Biofrontera Inc. Warrants
Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities
globenewswire.com
BFRI
BFRIW
Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma
globenewswire.com
BFRI
BFRIW
Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint
globenewswire.com
BFRI
BFRIW